Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Apr 08, 2023 7:02pm
175 Views
Post# 35385508

RE:RE:The number of Board Members

RE:RE:The number of Board MembersWe retail shareholder "mushrooms" (in the dark) can only hope that these two "strategic" moves of providing a larger pool (three more percent) of treasury shares for insiders, along with increasing the potential number of board members, both point to the  immiment major investment or buyout we all have been hoping for.

What did Matt say? Expect one or two ph 3 to start in the second half of this year. All logic says that requires a partner with money and expertise. 

We have been hoping that turns into a buy-out. Of course the share price has to increase first, to some decent level to justify a buyout at some lievel in the billions. And of course progress in the regulatory sphere along with maturing data will make the company more attractive.

So, a buyout should occur after a partnership to get things going on p 3s in two indications. Then the board will be expanded to accomodate our new partner, and the share price will go up, justifying giving more of the company to insiders.

Or so I am hoping for... as the penultimate chapters of this story before the final sale. 
<< Previous
Bullboard Posts
Next >>